Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Transcript
According to Cardinal Health’s 2022 report, only 40% of ophthalmologists reported being “very familiar” with biosimilars. What needs to be included in educational material aimed at these specialists specifically to increase that statistic?
Ophthalmology market research and our own market research at Cardinal Health has really revealed hesitation when it comes to biosimilars at this stage. In fact, when we looked at trends earlier when the first biosimilar was approved and launched in oncology, believe it or not, there were similar perceptions associated biosimilars amongst oncologists. Now, you see the strong adoption that we have an oncology today.
As we're entering these new therapeutic areas, with ophthalmology being the latest, we are seeing this hesitation and lack of familiarity, where there's a desire for more information and the need for more information to help build clinical confidence in these agents. So, any type of data or evidence in understanding of the FDA approval pathway and the associated scientific rigor from the FDA is key to helping build clinical confidence.
I will say in ophthalmology it's almost trickier because unlike oncology and rheumatology, there is not this robust international experience in ophthalmology with ophthalmology biosimilars. In fact, the US is going to be one of the first countries to have an ophthalmology biosimilar available. So, we are positioned to be a source of generating real-world evidence and data to support future confidence in these agents as more products are anticipated to come in the retina space.
Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis
December 3rd 2024The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.